Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension
A Pilot Phase IIa Randomised, Double-blind, Placebo-controlled, Crossover Study to Examine the Safety, Tolerability and Pharmacodynamic Effects on Blood Pressure of Repeat Oral Doses of SLx-2101 5, 10 or 20 mg Once Daily for up to 14 Days in Patients With Hypertension
Sponsor: Retension Pharmaceuticals. Inc.
A observational or N/A phase clinical study on Hypertension, this trial is completed. The trial is conducted by Retension Pharmaceuticals. Inc. and has accumulated 8 data snapshots since 2007. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Study Description(click to expand)1. Office seated peripheral systolic and diastolic blood pressure
2. Adverse events and vital signs
3. Plasma concentrations of SLx-2101
1. Office seated peripheral systolic and diastolic blood pressure 2. Adverse events and vital signs 3. Plasma concentrations of SLx-2101
Status Flow
Change History
8 versions recorded-
May 4, 2026 — Present [daily]
Completed
Phase: PHASE2 → None
-
Sep 2024 — May 2026 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jun 2023 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jul 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
The purpose is to determine the effective dosage and to study the effects of this dosage taken for 12 days on systolic and diastolic blood pressure in patients with hypertension.
Contact Information
- Retension Pharmaceuticals. Inc.
For direct contact, visit the study record on ClinicalTrials.gov .